Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 11/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 11/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 11/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 11/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 11/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 11/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | NOTCH1 | P46531 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.40 |
| ▸ | RET | P07949 | 2/20 | 0.40 |
| ▸ | APP | P05067 | 3/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21050358 | 1.00 | PSEN1 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL21050356 | 1.00 | PSEN1 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL21050357 | 1.00 | PSEN1 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL18970962 | 1.00 | PSEN1 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL30540111 | 1.00 | PSEN1 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL23881624 | 0.89 | GPR119 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL18971233 | 0.89 | GPR119 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL23881623 | 0.89 | GPR119 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL18952685 | 0.89 | GPR119 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL18971235 | 0.89 | GPR119 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018143-A1 | PROCESS FOR THE PREPARATION OF (9S)-N-[3-(6-METHYLPYRIMIDIN-4-YL)-3-AZABICYCLO[3.2.1]OCTAN-8-YL]-9-(2,3,4-TRIFLUOROPHENYL)-6,7,8,9-TETRAHYDRO-5H-[1,2,4]TRIAZOLO[1,5-A]AZEPIN-2-AMINE AND ITS SOLID FORM | HOFFMANN-LA ROCHE INC. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018143-A1 | PROCESS FOR THE PREPARATION OF (9S)-N-[3-(6-METHYLPYRIMIDIN-4-YL)-3-AZABICYCLO[3.2.1]OCTAN-8-YL]-9-(2,3,4-TRIFLUOROPHENYL)-6,7,8,9-TETRAHYDRO-5H-[1,2,4]TRIAZOLO[1,5-A]AZEPIN-2-AMINE AND ITS SOLID FORM | HOFFMANN-LA ROCHE INC. (US) | 2024-01-18 | — | — | US | disclosed |
| EP-4259630-A1 | PROCESS FOR THE PREPARATION OF (9S)-N-[3-(6-METHYLPYRIMIDIN-4-YL)-3-AZABICYCLO[3.2.1]OCTAN-8-YL]-9-(2,3,4-TRIFLUOROPHENYL)-6,7,8,9-TETRAHYDRO-5H-[1,2,4]TRIAZOLO[1,5-A]AZEPIN-2-AMINE AND ITS SOLID FORM | F. Hoffmann-La Roche AG (CH) | 2023-10-18 | — | — | EP | disclosed |
| WO-2022122864-A1 | PROCESS FOR THE PREPARATION OF (9S)-N-[3-(6-METHYLPYRIMIDIN-4-YL)-3-AZABICYCLO[3.2.1]OCTAN-8-YL]-9-(2,3,4-TRIFLUOROPHENYL)-6,7,8,9-TETRAHYDRO-5H-[1,2,4]TRIAZOLO[1,5-A]AZEPIN-2-AMINE AND ITS SOLID FORM | F. HOFFMANN-LA ROCHE AG (CH) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022122864-A1 | PROCESS FOR THE PREPARATION OF (9S)-N-[3-(6-METHYLPYRIMIDIN-4-YL)-3-AZABICYCLO[3.2.1]OCTAN-8-YL]-9-(2,3,4-TRIFLUOROPHENYL)-6,7,8,9-TETRAHYDRO-5H-[1,2,4]TRIAZOLO[1,5-A]AZEPIN-2-AMINE AND ITS SOLID FORM | F. HOFFMANN-LA ROCHE AG (CH) | 2022-06-16 | — | — | WO | disclosed |
| CN-109311878-B | Triazolopyridines as gamma-secretase modulators | 豪夫迈·罗氏有限公司 | 2022-05-24 | — | — | CN | disclosed |
| EP-3386978-B1 | BRIDGED PIPERIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2021-01-27 | — | — | EP | disclosed |
| US-20200291034-A1 | BRIDGED PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2020-09-17 | — | — | US | disclosed |
| US-10562903-B2 | Bridged piperidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20190010156-A1 | BRIDGED PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018143-A1 | PROCESS FOR THE PREPARATION OF (9S)-N-[3-(6-METHYLPYRIMIDIN-4-YL)-3-AZABICYCLO[3.2.1]OCTAN-8-YL]-9-(2,3,4-TRIFLUOROPHENYL)-6,7,8,9-TETRAHYDRO-5H-[1,2,4]TRIAZOLO[1,5-A]AZEPIN-2-AMINE AND ITS SOLID FORM | BACE1, APP, APH1B | PSEN1 5/4885PSEN2 7/4885APH1B 3/4885 |
| US-20200291034-A1 | BRIDGED PIPERIDINE DERIVATIVES | PTGDR, HPGDS, PSEN1 | PSEN1 3/4885PSEN2 21/4885APH1B 30/4885 |
| US-10562903-B2 | Bridged piperidine derivatives | PTGDR, HPGDS, PSEN1 | PSEN1 3/4885PSEN2 21/4885APH1B 30/4885 |
| US-20190010156-A1 | BRIDGED PIPERIDINE DERIVATIVES | PTGDR, HPGDS, PSEN1 | PSEN1 3/4885PSEN2 21/4885APH1B 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.